Covance and sanofi-aventis finalise r&d alliance

Published: 2-Nov-2010
Finance

Covance also acquires sanofi-aventis plants in France and the UK


Covance has finalised its deal with sanofi-aventis to become the French drugmaker’s research and development partner over the next 10 years.

Covance has also bought sanofi-aventis' Porcheville, France and Alnwick, UK sites and all employees will transfer to Covance.

The deal, announced on 29 September, is expected to generate revenues ranging from US$1.2bn to US$2.2bn over the next decade.

Covance, headquartered in Princeton, New Jersey, US provides drug development services to the pharmaceutical industry.

  • Companies:
  • Covance
  • Sanofi
See more

You may also like

Drug Delivery

Sanofi pledges to sell over €10bn in vaccine sales

Read more
In less than two years, Sanofi has delivered a competitive mRNA platform with improved potency and thermostability that performs with both viral and bacterial targets

Trending Articles

  1. Small molecules: big market opportunities The rapid rise of biologic drugs in recent years has been accompanied by a market narrative that suggests that innovation and new treatments will be fuelled by breakthroughs in this area, leading to a decline in the small molecule pipeline. This is far from true, notes Kevin Cook, Chief Executive Officer at Sterling Pharma Solutions; both are increasing and small molecule drugs continue to be a mainstay of many drug development portfolios
  2. Policy vacuum risks UK becoming a medicines supply backwater The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
  3. Lonza appoints President of Capsules and Health Ingredients Christian Seufert joins from BASF, where he has worked for the last 20 years. Most recently, he held the role of Senior VP for the Global Business Unit Pharma Solutions
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    The pros and cons of distribution agreements For life sciences companies seeking to break into overseas markets, distribution agreements are central to success
  5. AstraZeneca to stop production of Pulmicort pMDI Agreements with SkyePharma expected to be terminated

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Drug Delivery

Sanofi pledges to sell over €10bn in vaccine sales

In less than two years, Sanofi has delivered a competitive mRNA platform with improved potency and thermostability that performs with both viral and bacterial targets
Drug Delivery

Sanofi acquires Provention Bio and gains diabetes therapy

Following its acceptance of the tendered shares, Sanofi completed its acquisition of Provention Bio through the merger of a wholly owned subsidiary of Sanofi with and into Provention Bio
Regulatory

Sanofi's ALTUVIIIO approved by the US FDA

"This positive event triggers impairment reversal, positively impacting 2022 IFRS net income"
Manufacturing

Sanofi increases evergreen fund to $750m

The additional capital, confirmed by the executive committee, will also fuel the expansion and investment capacity of the Sanofi Ventures
Finance

Neuraxpharm to increase branded business by acquiring established Sanofi products

Neuraxpharm, the central nervous system (CNS) specialist, to acquire two portfolios of established products for CNS disorders, pain and vascular diseases
Research & Development

C4XD receives first milestone payment of €3 million from Sanofi

€3 million milestone payment triggered by preclinical progression in oral IL-17A inhibitor programme
Research & Development

Exscientia and Sanofi establish AI-based research collaboration

The companies will collaborate to identify and select target projects, leveraging Exscientia’s personalised medicine platform, designed to enable a patient-first approach
Subscribe now